All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MORF-057
Therapeutic Area: Gastroenterology Product Name: MORF-057
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2020
Details:
MORF-057 is in clinical development as an oral small molecule inhibitor of the α4β7 integrin for the treatment of inflammatory bowel disease (IBD) with an initial focus on ulcerative colitis (UC).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CERC-002
Therapeutic Area: Gastroenterology Product Name: AEVI-002
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 26, 2020
Details:
Cerecor has resumed the Phase 1b clinical study of CERC-002 in anti-TNF refractory adult Crohn’s patients with the lifting of the moratorium on elective endoscopy resulting from the COVID-19 pandemic.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IMU-856
Therapeutic Area: Gastroenterology Product Name: IMU-856
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 20, 2020
Details:
Immunic has dosed first healthy volunteer in the company’s phase 1 clinical program of IMU-856, an orally available, small molecule modulator that targets a yet undisclosed protein which serves as a transcriptional regulator of intestinal barrier function.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): L-Glutamine
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2020
Details:
The study is utilizing the same pharmaceutical-grade L-glutamine (PGLG) oral powder used in Endari® to evaluate the change in the number and size of colonic diverticula and assess safety.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): L-Glutamine
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Emmaus Life Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 16, 2020
Details:
Emmaus Life Sciences has engaged Partner International to lead the out-licensing activity for Emmaus’ prescription grade L-glutamine (PGLG) oral powder for use in the treatment of diverticulosis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): PT101
Therapeutic Area: Gastroenterology Product Name: PT101
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $75.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 29, 2020
Details:
Funds will be used in company's lead asset, PT101, a combination of an interleukin-2 mutein effector module with a protein backbone, designed to selectively expand regulatory T cells systemically without activating proinflammatory cells.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): OPL-002
Therapeutic Area: Gastroenterology Product Name: OPL-002
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 23, 2020
Details:
In the Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study, OPL-002 was well tolerated in a once-daily administration to healthy subjects for up to 28 days.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ABI-M201
Therapeutic Area: Gastroenterology Product Name: ABI-M201
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination June 18, 2020
Details:
Assembly Biosciences will regain worldwide rights to all microbiome candidates subject to the collaboration, including ABI-M201 and ABI-M301.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BT051
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2020
Details:
The Phase 1 clinical trial is evaluating various dose levels of BT051 for safety, tolerability and pharmacokinetics in a double-blind, placebo-controlled study in healthy volunteers.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): VE202
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: JSR LIFE SCIENCES CORP
Deal Size: $71.1 million Upfront Cash: Undisclosed
Deal Type: Series C Financing June 09, 2020
Details:
Proceeds from the financing will supoorts company's ongoing effort in advancing Phase 1 studies in healthy volunteers of VE202, the Company’s orally-administered live biotherapeutic product (LBP) candidate for inflammatory bowel disease (IBD).
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
